Cancer Therapeutics and Biotherapeutics Market (By Application: Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Others; By Top Selling Drugs: Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade; By Product Type: Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy, Others; By End User: Consumption, Household, Hospital) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030


The global cancer therapeutics and biotherapeutics market size was valued at US$ 161.76 billion in 2021 and is expected to hit US$ 339.44 billion by 2030 with a registered CAGR of 8.6% from 2022 to 2030.

Cancer Therapeutics and Biotherapeutics Market Size 2021 to 2030

Growth Factors

The cancer therapeutics and biotherapeutics are majorly used for the treatment of cancer. One of the primary factors boosting the growth of the global cancer therapeutics and biotherapeutics market is rising prevalence of cancer all around the globe over the projected period. The cancer is considered as high-risk disorder. That’s the reason; the market for cancer therapeutics and biotherapeutics is growing at a rapid pace.

The government and major market players are highly investing in research and development activities. This factor is helping in the development of new drugs and medications for the treatment of cancer. In addition, the market players are collaborating with each other for the development of cancer therapeutics and biotherapeutics in the global market. The introduction of new drugs and medicines is paving new way for the growth of the global cancer therapeutics and biotherapeutics market over the forecast period.

Furthermore, the growing geriatric population is contributing towards the expansion and development of the global cancer therapeutics and biotherapeutics market. The old people are more prone to such disorders and need utmost care and treatment. Thus, the cancer therapeutics and biotherapeutics help them to prevent against such disorders.

On the other hand, the factors such as negative impact of cancer therapeutics and biotherapeutics on the body and growing costs for development of cancer therapeutics and biotherapeutics are hindering the growth of the global cancer therapeutics and biotherapeutics market. In addition, the biotherapeutics are trending in the market for the treatment of cancer. The cancer therapeutics and biotherapeutics helps the human body to boost its immune system. The cancer patient needs strong immune system which is possible due to drugs and medicines.

Report Scope of the Cancer Therapeutics and Biotherapeutics Market

Report Coverage Details
Market Size by 2030 USD 339.44 Billion
Growth Rate from 2022 to 2030

CAGR of 8.6%

Largest Market North America
Fastest Growing Makret Asia Pacific
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Application, Top Selling Drugs, End User, Product, Geography
Companies Mentioned Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, Hoffmann-La Roche AG, EnGeneIC Ltd, Merck & Co Inc., Novartis, Pfizer Inc., Johnson & Johnson

 

The favorable government regulations and guidelines for the treatment of cancer is driving the growth of the global cancer therapeutics and biotherapeutics market. The number of drug manufacturers is involved in the manufacturing process of cancer therapeutics and biotherapeutics. The key market players are constantly adopting the marketing strategies for the growth and development of cancer therapeutics and biotherapeutics market.

Nowadays, the approvals on the drugs and medications by Food and Drug Administration (FDA) are quite easy. This factor is encouraging market players to develop new products in the cancer therapeutics and biotherapeutics market. Moreover, the market players are collaborating with logistics companies for supplying drugs and medicines on an international level. This factor is supporting the growth of the global cancer therapeutics and biotherapeutics market over the forecast period.

The COVID-19 outbreak had affected healthcare sector significantly. This has directly impacted the growth of the global cancer therapeutics and biotherapeutics market. Even during the coronavirus outbreak, the demand for cancer therapeutics and biotherapeutics was stable in nature. But the supply chain disruptions and closure of manufacturing units caused negative impact on the cancer therapeutics and biotherapeutics market. Thus, the cancer therapeutics and biotherapeutics market is expected to recover as restrictions are being removed from all the regions all around the globe.

The government of developed and developing regions is constantly contributing towards the growth of the cancer therapeutics and biotherapeutics market. The government of such regions is trying to create manufacturing hubs in regions with low labor costs. This factor is driving the growth of the global cancer therapeutics and biotherapeutics market during the forecast period.

Application Insights

The lung cancer segment dominated the cancer therapeutics and biotherapeutics market in 2021. The lung cancer is the most common cancer killer, accounting for about a quarter of all cancer fatalities. The lung cancer kills more people than breast cancer, colon cancer, and prostate cancer combined every year. Thus, the lung cancer segment is growing at a rapid pace.

The head and neck cancer segment is fastest growing segment of the cancer therapeutics and biotherapeutics market in 2021. The rising incidences of cancer are driving the segment growth. In the U.S., head and neck cancer accounts for around 4% of all cancers. Thus, this factor is driving the growth of the segment over the projected period.

Top Selling Drugs Insights

The Revlimid segment dominated the cancer therapeutics and biotherapeutics market in 2021. The Revlimid is used in the treatment of wide range of cancers. This drug helps to increase the life expectancy rate of cancer patients. In addition, Revlimid contains lenalidomide, which treat myeloma and myelodysplastic syndrome. As a result, the growing prevalence of cancer disorders is driving the growth of the segment.

The Zytiga segment is fastest growing segment of the cancer therapeutics and biotherapeutics market in 2021. Zytiga contains abiraterone acetate which is mainly used in the treatment of the prostate cancer. This drug is approved by Food and Drug Administration (FDA). The doctors recommend to avoid overdoses of Zytiga. This can also lead to death and fatalities.

Region Insights

North America dominated the cancer therapeutics and biotherapeutics market in 2021. The presence of vast number of market players is driving the growth of the cancer therapeutics and biotherapeutics market. Another factor driving the growth of the cancer therapeutics and biotherapeutics market in North America region is growing prevalence of cancers such as breast cancer, prostate cancer, and lung cancer.

Cancer Therapeutics and Biotherapeutics Market Share, By Region, 2021 (%)

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. China and Indiadominate the cancer therapeutics and biotherapeutics market in Asia-Pacific region. The cancer therapeutics and biotherapeutics market in Asia-Pacific region is growing due to the growing awareness about the cancer in countries such as India, China, South Korea, and Japan. The government of these countries is highly investing in research and development activities. In addition, the growing geriatric population is also boosting the growth of the cancer therapeutics and biotherapeutics market in the region during the forecast period.

Key Developments

  • Janssen’s Zytiga was licensed by Health Canada in February 2018 for the diagnosis and treatment of patients with newly diagnosed high risk prostate cancer who had received up to 3 months of past ADT.
  • In April 2018, Swissmedic approved Roche’s Alecensa as a first line treatment of patients with advanced or metastatic quasi cell lung cancer who are ALK positive.
  • The FDA authorized Roche’s skin cancer medicine Zelboraf for patients with Erdheim-Chester Diseases, a rare kind of blood cancer in November 2017.

Some of the prominent players in the global cancer therapeutics and biotherapeutics market include:

  • Amgen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • ELI Lilly and Company
  • Hoffmann-La Roche AG
  • EnGeneIC Ltd
  • Merck & Co Inc.
  • Novartis
  • Pfizer Inc.
  • Johnson & Johnson

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Application

  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Giloblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others

By Top Selling Drugs

  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Termodar
  • Others

By Product Type

  • Chemotherapy
  • Radiation Therapy
  • Hormone Therapy
  • Biotherapy
  • Others

By End User

  • Consumption (Sales)
  • Household
  • Hospital

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of cancer therapeutics and biotherapeutics market?
The global cancer therapeutics and biotherapeutics market size was reached at US$ 161.76 billion in 2021 and is anticipated to rake US$ 339.44 billion by 2030.
The global cancer therapeutics and biotherapeutics market is growing at a CAGR of 8.6% from 2022 to 2030.
The major players operating in the cancer therapeutics and biotherapeutics market are Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, Hoffmann-La Roche AG, EnGeneIC Ltd, Merck & Co Inc., Novartis, Pfizer Inc., and Johnson & Johnson.
The government and big market participants are heavily spending in research and development. This factor is assisting in the creation of novel cancer treatments and therapies. Furthermore, market participants are collaborating on the development of cancer therapies and biotherapeutics.
North America is the largest segment for cancer therapeutics and biotherapeutics market and will lead in near future.

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample